Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2960224 | 0.88 | SLC37A4 (0.38) | SLC37A4 | |
| SCHEMBL2959701 | 0.82 | SLC37A4 (0.38) | SLC37A4 | |
| SCHEMBL2955820 | 0.75 | SLC37A4 (0.46) | SLC37A4 | |
| SCHEMBL2947006 | 0.74 | SLC37A4 (0.48) | SLC37A4 | |
| SCHEMBL2948794 | 0.72 | SLC37A4 (0.44) | SLC37A4 | |
| SCHEMBL4451751 | 0.70 | SLC37A4 (0.32) | SLC37A4 | |
| SCHEMBL2955955 | 0.70 | SLC37A4 (0.45) | SLC37A4 | |
| Anthraquinone SCHEMBL2946623 | 0.70 | SLC37A4 (0.45) | SLC37A4 | |
| Anthraquinone SCHEMBL2948902 | 0.68 | SLC37A4 (0.48) | SLC37A4 | |
| SCHEMBL2946624 | 0.66 | SLC37A4 (0.48) | SLC37A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763740-B2 | Method for the production of mumbaistatin derivatives | SANOFI-AVENTIS (FR) | 2010-07-27 | — | — | US | disclosed |
| US-20090156836-A1 | METHOD FOR THE PRODUCTION OF MUMBAISTATIN DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156836-A1 | METHOD FOR THE PRODUCTION OF MUMBAISTATIN DERIVATIVES | MMAB, MLYCD, HMBS | SLC37A4 4052/4885S1PR1 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.